Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The requested reference [215bb7bb16a77aa7ca23ac510a883967765057de] no longer exists in our database. It has been replaced by the current reference: [f571f57e1967080c8a1870d8405d5f940113c580]

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
To evaluate the efficacy and safety of venetoclax, chidamide, and chiglitazar sodium (VCC) in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
Epistemonikos ID: a5b597df4a81226e3e06c7a7eede480f20a1736a
First added on: Aug 26, 2026